Ocular Therapeutix, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ocular Therapeutix, Inc. - overview
Established
2006
Location
Bedford, MA, US
Primary Industry
Biotechnology
About
Founded in 2006 and based in Massachusetts, US, Ocular Therapeutix Inc. operates as a provider of ophthalmic therapeutic products for ophthalmology and ophthalmic surgery applications. In February 2024, Deep Track Capital, Venrock, TCG Crossover Management, Perceptive Advisors, Great Point Partners, Logos Capital, Surveyor Capital, Acuta Capital Partners, and Opaleye Management agreed to invest approximately USD 325 million in Ocular Therapeutix, Inc. , before deducting placement agent fees and other offering expenses.
As of 2024, the company is headed by its CEO Pravin U. Dugel. The company bears the ticker symbol NASDAQ: OCUL. Ocular Therapeutix’s product portfolio includes sustained-release therapies designed to enhance patient compliance and treatment outcomes.
Key products include DEXTENZA® and ReSure® Sealant, which are used for managing post-surgical inflammation and sealing incisions, respectively. The company is also developing new therapies using its ELUTYX™ technology, which allows for sustained drug release and has the potential to transform treatments for retinal diseases, glaucoma, and other ophthalmic conditions.
Current Investors
Surveyor Capital, Acuta Capital Partners, Opaleye Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.ocutx.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Ocular Therapeutix, Inc. - timeline of key events
Ocular Therapeutix, Inc. - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 772,000 | 1,750,000 | 1,887,000 | 1,923,000 | 1,990,000 | 4,227,000 | 17,403,000 | 43,522,000 | 51,494,000 | - | - | - |
| % Revenue Growth (YoY) | - | 126.7% | 7.8% | 1.9% | 3.5% | 112.4% | 311.7% | 150.1% | 18.3% | - | - | - |
| EBITDA (USD) | (26,523,000) | (37,160,000) | (42,259,000) | (60,281,000) | (56,832,000) | (83,272,000) | (60,074,000) | (75,616,000) | (76,545,000) | - | - | - |
| Operating Income (USD) | (27,094,000) | (38,197,000) | (43,326,000) | (61,923,000) | (59,118,000) | (85,802,000) | (62,847,000) | (78,037,000) | (78,654,000) | - | - | - |
| Operating Margin | (3509.6%) | (2182.7%) | (2296.0%) | (3220.1%) | (2970.8%) | (2029.9%) | (361.1%) | (179.3%) | (152.7%) | - | - | - |
| % EBITDA Margin | (3435.6%) | (2123.4%) | (2239.5%) | (3134.7%) | (2855.9%) | (1970.0%) | (345.2%) | (173.7%) | (148.6%) | - | - | - |
| NET Income (USD) | (28,648,000) | (39,748,000) | (44,703,000) | (63,386,000) | (59,978,000) | (86,372,000) | (155,636,000) | (6,553,000) | (71,038,000) | - | - | - |
| % Net Margin | (3710.9%) | (2271.3%) | (2369.0%) | (3296.2%) | (3014.0%) | (2043.3%) | (894.3%) | (15.1%) | (138.0%) | - | - | - |
Ocular Therapeutix, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Ocular Therapeutix, Inc. | - |
Displaying 1 - 1 of 1
Ocular Therapeutix, Inc. - employee data
Ocular Therapeutix, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| - | BM | ||||||
| Board Director | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.